Opdivo

Bavarian and BMS press on with Opdivo and cancer vaccine combo

https://pharmaphorum.com/news/bavarian-bms-press-opdivo-cancer-vaccine-combo/

Promise for combination approach to cancer

https://pharmaphorum.com/views-and-analysis/promise-combination-approach-cancer/

Imbruvica, Opdivo and Praluent gain approvals for Scotland’s NHS

https://pharmaphorum.com/news/imbruvica-opdivo-praluent-gain-approvals-scotlands-nhs/

BMS’ Opdivo stumbles in lung cancer, but could still maintain lead

https://pharmaphorum.com/news/opdivo-stumbles-lung-cancer-still-maintain-lead/

Ambition trips BMS as Opdivo fails in frontline lung cancer

https://pharmaphorum.com/news/shock-opdivo-fails-front-line-lung-cancer/

BMS files Opdivo for new use in US and Europe

https://pharmaphorum.com/news/bms-files-opdivo-new-use-us-eu/

NICE rejects Opdivo in advanced kidney cancer

https://pharmaphorum.com/news/nice-rejects-bms-opdivo-advanced-kidney-cancer/

The HNSCC immunotherapy race is on – and it’s going to be close

https://pharmaphorum.com/partner-content-oncology/hnscc-immunotherapy-race-going-close/

10 drugs – and their prices – which changed pharma in 2015

https://pharmaphorum.com/views-and-analysis/10-drugs-and-their-prices-which-changed-pharma-in-2015/

«< 2 3 4 5 6

Close in 10 seconds

Pharmaphorum.com

Search